Anumana, Inc.
Anumana is an AI-driven health technology company leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. The company was founded by nference and Mayo Clinic to leverage both organizations' clinical and technical expertise to develop innovative AI technology applied to ECG, electrophysiology, and hemodynamics, from an investigational resource to a meaningful tool for clinicians to advance patient care. Anumana's software as a medical device (SaMD) solutions aim to detect hidden diseases using ECG-AI algorithms to enhance and improve care through real-time AI insights. Anumana SaMDs are designed for real-world physician use, integrating into existing workflows at the point of care to reduce costs and enhance quality of life. Anumana's algorithms have been evaluated in retrospective and prospective studies with nearly 100 peer-reviewed publications. In addition to the company's first FDA-cleared algorithm, ECG-AI LEF, to detect low ejection fraction, three Anumana algorithms have received FDA Breakthrough Device Designation and are currently undergoing clinical validation to support regulatory submissions.